CPRX
CatalystCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The $31.50 all-cash Angelini deal provides a near-term valuation floor, the FIRDAPSE settlement removes a key legal overhang, and Q1 results showed continued revenue growth, cash generation, and no funded debt.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
If the transaction fails, FYCOMPA revenue is already in steep decline after loss of exclusivity, which weakens standalone earnings durability.
Momentum
36
Value
67
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.50 · Bull $31.55 · Bear $27.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-15 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $31.67
Why
Momentum36 · Δ7d +20.5
Value67 · Δ7d -0.1
Sentiment44 · Δ7d -1.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
36
26% active weight
Current posture
7d trendImproving
Δ7d
+20.5
Δ21d
-18.9
Value
67
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
44
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
+0.6
Why this grade
Composite grade C. Momentum 36.3 / Value 66.8 / Sentiment 44.1
Fundamentals (TTM)As of 2026-07-15
Fundamentals (TTM)
As of 2026-07-15
Market Cap
$3.85B
Beta
0.73
Shares Out
122.42M
P/E (TTM)
13.3
P/S (TTM)
4.85
P/FCF (TTM)
11.95
Rev YoY
+5.6%
EPS YoY
+12.4%
Gross Margin
+79.6%
Op Margin
+44.8%
Net Debt
-$706.38M
Current Ratio
7.10
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology